PD-1 Immunotherapy
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer (NCT06485271) | Changzhi People's Hospital Affiliated to Changzhi Medical College | 2023-11-01 |
| PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery (NCT05468138) | Fudan University | 2022-08-01 |
| Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma (NCT05265793) | Fudan University | 2021-11-21 |
Track PD-1 Immunotherapy automatically
Every clearance here is in the API, with alerts when new ones post.